- Oops!Something went wrong.Please try again later.
Leuven, BELGIUM, Boston, MA, US – JUNE 3, 2022 – Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company developing next generation standard of care ophthalmic therapies, with clinical stage assets in vascular retinal disorders, today announced that two abstracts will be presented at The Macula Society 45th Annual Meeting, June 8 -11, 2022 in Berlin, Germany.
THR-149 is a potent plasma kallikrein inhibitor being developed as a potential new standard of care for the up to 50% of diabetic macular edema (DME) patients showing suboptimal response to anti-VEGF therapy. Oxurion is evaluating THR-149 for the treatment of DME in Part B, the second part of its two-part Phase 2 KALAHARI trial.
TITLE: KALAHARI: Part A Results of the Phase 2 Study of THR-149, a Plasma Kallikrein Inhibitor, in Subjects with DME Responding Sub optimally to anti-VEGF Treatment
PRESENTER: Shree K. Kurup, MD, Dept. of Ophthalmology, University Hospitals, Cleveland, OH
PRESENTATION DATE AND TIME: Friday, June 10, 2022, 7:50 a.m. CET
THR-687 is a highly selective pan-RGD integrin antagonist that Oxurion had been developing as a first line therapy for DME patients. Recently released data from Part A, the first part of its two-part Phase 2 INTEGRAL trial showed THR-687 to be safe and well tolerated with no serious adverse events and none of the patients requiring rescue medication through Month 3, however, there was insufficient evidence of efficacy on the key endpoints (Best-Corrected Visual Acuity and Central Subfield Thickness). As a result, Oxurion has decided not to advance THR-687 to Part B of the INTEGRAL trial.
TITLE: THR-687, a Potent and Highly Selective RGD Integrin Inhibitor in Development for the Treatment of Diabetic Macular Edema
PRESENTER: Francesco Bandello, Professor and Chairman of the Department of Ophthalmology, VitaSalute, Milan, Italy
PRESENTATION DATE AND TIME: Thursday, June 9, 2022, 8:44 a.m. CET
Oxurion (Euronext Brussels: OXUR) is a biopharmaceutical company developing next generation standard of care ophthalmic therapies, which are designed to improve and better preserve vision in patients with retinal disorders including diabetic macular edema (DME), the leading cause of vision loss in working-age people, as well as other conditions. Oxurion intends to play an important role in the treatment of retinal disorders, including the successful development of THR-149, its novel therapeutic for the treatment of DME. THR-149 is a potent plasma kallikrein inhibitor being developed as a potential new standard of care for the up to 50% of DME patients showing suboptimal response to anti-VEGF therapy. Oxurion is headquartered in Leuven, Belgium, with corporate operations in Boston, MA. More information is available at www.oxurion.com.
For more information, please contact: